Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Immunovant (NASDAQ:IMVT) on Monday, setting a price target of $54, which is approximately 27.21% above the present share price of $42.45.
Archila expects Immunovant to post earnings per share (EPS) of -$0.25 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in Immunovant, with an average price target of $56.89.
The analysts price targets range from a high of $64 to a low of $49.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$20.97 million. The company's market cap is $3.47 billion.
According to TipRanks.com, Stifel Nicolaus analyst Derek Archila is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.3% and a 51.34% success rate.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.